CD47 and glioblastoma: An IgG1 form of anti-CD47 antibody should possess ADCP and ADCC anti-GBM activity; however, infusion toxicities and difficulty in penetration through the blood−brain barrier (BBB) are current challenges that limit the systemic treatment of GBM with an IgG1 form of anti-CD47 antibody.